IPhEB Forum 2-3 April 2019, St. Petersburg
On April 2, within the framework of the thematic session of the IPhEB Forum, industry professionals discussed important issues on the development of biotechnologies of future.
Specialists of group of companies X-Tech were speakers at the thematic session “Development of the biotechnological direction in the pharmaceutical industry” and examined current issues of the field.
Alexey Martynov, General Director of X-Biocell and President of the Association of Manufacturers of Biomedical Cell Products.
“Russia has already done quite a lot of research and development in the field of Biomedical Cell Products and it’s quite realistic in ten years to outperform in output volumes of these products both the USA and the EU. But for this it is necessary to coordinate the work of scientists, so that they do not duplicate each other in their research, solve some questions on preclinical studies conduction which still exist, establish and license production centers where it will be possible to produce Biomedical Cell Products for clinical research (according to Federal Law No. 180, Biomedical Cell Products produced at licensed production sites are allowed for clinical trials). And for all this, huge financial resources and qualified personnel are needed. For the organization of cooperation and interaction of all interested participants of the BMKP industry, the Association of Manufacturers of Biomedical Cell Products. was created. ”
Dmitry Polstyanov, General Director of X-Tech, spoke about the scaling process in biotechnological production. He reported in detail about the requirements for such production and about tasks that need to be resolved when these production are created. For specific examples, a technological process for the production of some biomedical products was described. The companies listed are world leaders in the production of equipment for biotechnologies, also there were given recommendations are given on the choice of equipment for the production of the main biomedical preparations.
Alexey Lundup, executive director of the Association of Manufacturers of Biomedical Cell Products: “Today, the global market for the production of biological products is estimated at $ 13.3 billion, of which almost equal parts (9.7 billion and 7.6 billion) are spent on two areas - genetic engineering and cell therapy. The average annual growth rate of the market for these drugs is 22% and, according to experts, in a few years the amount of expenses in this area will grow to $ 500 billion. At the same time, the creation of a product and its commercialization take from seven to ten years, but, as in the "chemical" pharmaceutical field, not all preparations reach the finish line. In the world today, more than seven hundred companies are working in the field of cell therapy, the leaders are the United Kingdom, the United States, Japan and South Korea, ” Alexey told to the session participants. - More than 30 thousand patents have already been protected, but as of yet only 30 products have been registered. The leader of this trend, the United Kingdom, spends on average about half a billion pounds on the development of Biomedical Cell Products. Cell Therapy Catapult has been established in the country for cooperation in research, industry and regulatory agencies. As a result of its activities, it is possible to bring the product to the market in seven years, which is considered to be a fairly rapid promotion.”